Sammons, Sarah
Kornblum, Noah S.
Blackwell, Kimberly L.
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
First Online: 22 August 2018
Change Date: 8 December 2018
Change Type: Correction
Change Details: The article Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer, written by Sarah Sammons, Noah S. Kornblum and Kimberly L. Blackwell, was originally published electronically on the publisher’s internet portal (currently SpringerLink).
Compliance with Ethical Standards
:
: Medical writing support was provided by Abbie Saunders PhD and Dean Clarke PhD (Articulate Science Ltd). Financial support for medical editorial assistance and funding for open access publication were provided by Novartis Pharmaceuticals Corporation. Novartis Pharmaceuticals Corporation did not influence the content of the manuscript.
: Kimberly Blackwell received grants paid to institution from AstraZeneca, Genentech, Novartis, and Pfizer; received honoraria from Advaxis, AstraZeneca, Bayer, Celgene, Celldex, Celltrion, Coherus Biosciences, Eisai, Eli Lilly, Genentech, GI Therapeutics, MacroGenics, Merck, Mylan GmbH, Novartis, Pfizer, Pierian Biosciences, Puma, Roche, Sandoz, Seattle Genetics, Syndax, and Visante; and is now employed by Eli Lilly. Sarah Sammons and Noah Kornblum have declared no conflicts of interest.